價(jià)格 | ¥213 | ¥642 | ¥990 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 Cinaciguat | 英文名稱:Cinaciguat |
CAS:329773-35-5 | 品牌: TargetMol |
產(chǎn)地: 美國(guó) | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.82% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T1984 |
名稱 | Cinaciguat |
描述 | Cinaciguat (BAY 58-2667) (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure. |
激酶實(shí)驗(yàn) | HDAC Inhibition Assays: Purified HDACs are incubated with 1 mM carboxyfluorescein (FAM)-labeled acetylated peptide substrate and test compound for 17 h at 25 °C in HDAC assay buffer containing 100 mM HEPES (pH 7.5), 25 mM KCl, 0.1% BSA, and 0.01% Triton X-100. Reactions are terminated by the addition of buffer containing 0.078% SDS for a final SDS concentration of 0.05%. Substrate and product are separated electrophoretically using a Caliper LabChip 3000 system with blue laser excitation and green fluorescence detection (CCD2). The fluorescence intensity in the substrate and product peaks is determined using the Well Analyzer software on the Caliper system. The reactions are performed in duplicate for each sample. IC50 values are automatically calculated using the IDBS XLFit version 4.2.1 plug-in for Microsoft Excel and the XLFit 4-Parameter Logistic Model: ((A+((B_A)/1+((C/x)D)))), in which x is compound concentration, A and B are respectively the estimated minimum and maximum of percent inhibition, C is the inflection point, and D is the Hill slope of the sigmoidal curve. The standard errors of the IC50 values are automatically calculated using the IDBS XLFit version 4.2.1 plug-in for Microsoft Excel and the formula xf4_FitResultStdError. |
體外活性 | Cinaciguat(10 μM)顯著增強(qiáng)細(xì)胞內(nèi)cGMP生成,同時(shí)對(duì)細(xì)胞收縮和鈣瞬變沒有劑量依賴性影響[2]。 |
體內(nèi)活性 | Cinaciguat (10 mg/kg/天, p.o.) 在糖尿病大鼠中的治療不會(huì)影響血糖水平,同時(shí)能夠減少水?dāng)z入量。Cinaciguat治療能夠緩解糖尿病相關(guān)的氧化應(yīng)激,保護(hù)免受DM相關(guān)NO-sGC-cGMP-PKG信號(hào)途徑的改變,同時(shí)減輕糖尿病相關(guān)的心肌肥厚和凋亡[1]。Cinaciguat(1-10-100 nM)在WT和apo-sGC小鼠的條帶中誘導(dǎo)濃度依賴性的松弛,但對(duì)由PGF2α在WT或apo-sGC條帶中誘導(dǎo)的相位活動(dòng)沒有任何影響[3]。 |
存儲(chǔ)條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 45 mg/mL (79.55 mM) |
關(guān)鍵字 | Inhibitor | inhibit | Cinaciguat | Guanylate Cyclase |
相關(guān)產(chǎn)品 | Nelociguat | Vericiguat | Methylene Blue | Methylene Blue trihydrate | BAY 41-2272 | Nitroprusside disodium dihydrate | LY83583 | NS-2028 | Riociguat | Sinitrodil | ODQ | Lificiguat |
相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | ReFRAME 相關(guān)化合物庫(kù) | 抗COVID-19化合物庫(kù) | GPCR靶點(diǎn)分子庫(kù) | 臨床期小分子藥物庫(kù) | 膜蛋白靶向化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù) |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬(wàn)人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營(yíng)行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營(yíng)模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP7年
|
臺(tái)州市科瑞生物技術(shù)有限公司
|
2024-12-11 | |
詢價(jià) |
VIP2年
|
陜西西化化學(xué)工業(yè)有限公司
|
2025-02-19 | |
詢價(jià) |
VIP5年
|
山東沃德森生物科技有限公司
|
2025-02-12 | |
詢價(jià) |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-02-16 | |
¥1999.90 |
VIP2年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |